Condition: Fungal Infection · Haematological Malignancy · Blood Cancer · Sponsor: The University of Queensland
This project aims to address invasive fungal infections in patients, by precision dosing of voriconazole based on CYP2C19 genotype testing with Bayesian dose-forecasting dosing software to develop patient-centric and maximally effective dosing regimens. This study investigates if voriconazole increases the proportion of patients achieving therapeutic exposure at day 8 of dosing compared with standard care; and will assess factors that influence the implementation of genotype testing and dosing software in the healthcare system, including fidelity, feasibility, acceptability and cost-effectiveness. It will recruit at least 104 kids and adults in a parallel-group randomised clinical trial. A hybrid feasibility sub-study will assess the scalability of genotype-directed dosing to ensure sustainable integration of the interventions into the clinical workflow. A health economic sub-study will evaluate the costs, health outcomes and cost-effectiveness of genotype-directed testing compared to standard care.
This description comes directly from the study's public registry record.
Jason A Roberts, PhD · +61 7 3346 5032 · j.roberts2@uq.edu.au
Luminita Vlad · 61 7 3346 5045 · l.vlad@uq.edu.au
Always discuss trial participation with your own doctor first.
| Fred Hutchinson Cancer Centre | Seattle, Washington, United States | Recruiting |
| Sydney Children's Hospital Network | Sydney, New South Wales, Australia | Recruiting |
| Westmead Hospital | Sydney, New South Wales, Australia | Recruiting |
| Royal Brisbane & Women's Hospital | Brisbane, Queensland, Australia | Recruiting |
| Children's Hospital Queensland | South Brisbane, Queensland, Australia | Recruiting |
| Royal Adelaide Hospital | Adelaide, South Australia, Australia | Recruiting |
| Peter MacCallum Cancer Centre | Melbourne, Victoria, Australia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06510699